Powered by HealthTechMovers.com
We added 4 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
Vaxcyte, Inc., PCVX
Summary: Vaxcyte Inc.is a biopharmaceutical company develops vaccines for infectious diseases. It offers conjugate, pneumococcal conjugate and complex antigen-based vaccines. Vaxcyte Inc.is based in Foster City, California.
- Last Price: $72.36
- Price Change: $0.81, 1.13%
- Yearly Gain: 75.46%
- Market Cap: $7.84B
- P/E Ratio: -17.52
Here are 3rd party ratings for PCVX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 32% (80 out of 252)
What is the sentiment on the street regarding Vaxcyte, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in PCVX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on PCVX before you decide to make any investment.
Click here for chart >>
Celldex Therapeutics, Inc., CLDX
Summary: CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
- Last Price: $50.00
- Price Change: $-0.72, -1.41%
- Yearly Gain: 11.08%
- Market Cap: $2.79B
- P/E Ratio: -17.54
Here are 3rd party ratings for CLDX:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 32% (80 out of 252)
What is the sentiment on the street regarding Celldex Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in CLDX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on CLDX before you decide to make any investment.
Click here for chart >>
Viridian Therapeutics, Inc., VRDN
Summary: Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.
- Last Price: $18.14
- Price Change: $-0.91, -4.78%
- Yearly Gain: -44.44%
- Market Cap: $1.14B
- P/E Ratio: -3.56
Here are 3rd party ratings for VRDN:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 32% (80 out of 252)
What is the sentiment on the street regarding Viridian Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bearish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Balanced
- Investor Sentiment: Positive
- Hedge Fund signal: High Risk
If you are interested in VRDN or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on VRDN before you decide to make any investment.
Click here for chart >>
Y-mAbs Therapeutics, Inc., YMAB
Summary: Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA.
- Last Price: $16.92
- Price Change: $-0.41, -2.37%
- Yearly Gain: 316.75%
- Market Cap: $740.71M
- P/E Ratio: -40.29
Here are 3rd party ratings for YMAB:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 32% (80 out of 252)
What is the sentiment on the street regarding Y-mAbs Therapeutics, Inc. ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Bullish
- Blogger Consensus:
- Media Buzz: Neutral
- Insider Signal: Selling
- Investor Sentiment: Positive
- Hedge Fund signal: Medium Risk
If you are interested in YMAB or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on YMAB before you decide to make any investment.
Click here for chart >>
Thanks for reading!